Ionis Pharmaceuticals announced positive topline results from its pivotal Phase 1-3 study of zilganersen for Alexander disease (AxD), a rare and often fatal neurological condition.

Johnson & Johnson's 8-K filing on April 14, 2026, reveals their Q1 2026 financial results and a significant dividend increase. The company announced a 3.

BeOne Medicines Ltd. (BGNE) filed an 8-K on April 14, 2026, pertaining to its 2025 Annual Report filed with the Shanghai Stock Exchange's STAR Market.

Johnson & Johnson's 8-K filing on April 14, 2026, reveals their Q1 2026 financial results and a significant dividend increase.

AbbVie announced an update to its 2026 earnings guidance in an 8-K filing on April 3, 2026. The update reflects a $744 million pre-tax charge for acquired IPR&D (In-Process Research and Development) a...